Flex Pharma, Inc. (NASDAQ: FLKS) today announced that it is prioritizing its clinical programs in the severe neurological diseases of amytrophic lateral sclerosis (ALS), multiple sclerosis (MS) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results